A polyclonal antiserum against chromogranin A and B - a new sensitive marker for neuroendocrine tumours

Eriksson, Barbro; Arnberg, Henrik; Öberg, Kjell; Hellman, Urban; Lundqvist, G.; Wernstedt, Christer; Wilander, Erik

doi:10.1530/acta.0.1220145

Cited by 79 publications

(45 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, we confirm that plasma CgA is an excellent predictor of disease, especially in gastroenteropancreatic tumours Eriksson et al, 1990;Nobels et al, 1997;Baudin et al, 1998) which were identified in all cases. As already reported for phaeochromocytomas, in this group a frequent cosecretion of CgA and of other tumoral markers was likewise observed (Nobels et al, 1997;Baudin et al, 1998) and CgA was sometimes found to be the only humoral predictor of disease (Baudin et al, 1998;Ferrari et al, 1998;Nobels et al, 1998).…”

Section: Discussionsupporting

confidence: 76%

A New Human Chromogranin “A” Immunoradiometric Assay for the Diagnosis of Neuroendocrine Tumours

Bernini

Moretti

Ferdeghini

et al. 2000

Journal of Hypertension

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 76%

A New Human Chromogranin “A” Immunoradiometric Assay for the Diagnosis of Neuroendocrine Tumours

Bernini

Moretti

Ferdeghini

et al. 2000

Journal of Hypertension

View full text Add to dashboard Cite

“…Levels of total circulating hCgA are significantly elevated in phaeochromocytomas, carcinoid and pancreatic endocrine tumours (O'Connor and Deftos, 1986). These data have been confirmed and extended to other neoplasia: neuroblastoma and gastrointestinal tumours (Eriksson et al, 1990;Hsiao et al, 1990;Stridsberg et al, 1995). Other authors have also described how the occurrence of plasma hCgA in prostatic carcinoma may be the sign of an unfavourable evolution (Cussenot et al, 1996;Deftos et al, 1996).…”

mentioning

confidence: 72%

A new human chromogranin A (CgA) immunoradiometric assay involving monoclonal antibodies raised against the unprocessed central domain (145-245)

Degorce¹,

Goumon

Jacquemart³

et al. 1998

Br J Cancer

View full text Add to dashboard Cite

Chromogranin A (CgA), a major protein of chromaffin granules, has been described as a potential marker for neuroendocrine tumours. Because of an extensive proteolysis which leads to a large heterogeneity of circulating fragments, its presence in blood has been assessed in most cases either by competitive immunoassays or with polyclonal antibodies. In the present study, 24 monoclonal antibodies were raised against native or recombinant human CgA. Their mapping with proteolytic peptides showed that they defined eight distinct epitopic groups which spanned two-thirds of the C-terminal part of human CgA. All monoclonal antibodies were tested by pair and compared with a reference radioimmunoassay (RIA) involving CGS06, one of the monoclonal antibodies against the 198–245 sequence. It appears that CgA C-terminal end seems to be highly affected by proteolysis and the association of C-terminal and median-part monoclonal antibodies is inadequate for total CgA assessment. Our new immunoradiometric assay involves two monoclonal antibodies, whose contiguous epitopes lie within the median 145–245 sequence. This assay allows a sensitive detection of total human CgA and correlates well with RIA because dibasic cleavage sites present in the central domain do not seem to be affected by degradation. It has been proved to be efficient in measuring CgA levels in patients with neuroendocrine tumours. © 1999 Cancer Research Campaign

show abstract

“…Since then, other assays for measurements of hCgA (Dillen et al 1989, O'Connor et al 1989, Eriksson et al 1990, Bender et al 1992, Stridsberg et al 1993, Syversen et al 1994, Corti et al 1996 and bCgA have been reported (Dillen et al 1989, Kawakubo et al 1989. Regionspecific assays for the determination of CgA and CgB have also been published (Tateishi et al 1989, Iguchi et al 1990, McGrath-Linden et al 1991, Kirchmair et al 1994, Syversen et al 1994, Stridsberg et al 1995.…”

Section: Discussionmentioning

confidence: 99%

Characterisation of N-terminal chromogranin A and chromogranin B in mammals by region-specific radioimmunoassays and chromatographic separation methods

Stridsberg

Angeletti²,

Helle³

2000

Journal of Endocrinology

View full text Add to dashboard Cite

Chromogranin A (CgA) and chromogranin B (CgB) are acidic proteins stored in and released from hormone granules in endocrine and neuroendocrine tissue. The chromogranins are postulated to serve as pro-hormones to generate biologically active peptides, which may influence hormonal release and vascular functions or have antibacterial functions. Although N-terminal and C-terminal regions show some species amino acid homology, the chromogranins as a whole display considerable interspecies differences, which prevents their use in comparative studies of biological functions.We present four new radioimmunoassays for the measurement of defined N-terminal regions of CgA and CgB. A new radioimmunoassay for measurement of intact bovine CgA has also been developed. With these assays and two previously published ones, we have compared the cross-reactivity of chromogranins from man, cattle, sheep, goat, pig and horse and compared adrenomedullar content and serum levels of CgA from these species. We have also studied the influence of peptide concentrations and the ionic strength of the mobile phase on molecular weight estimations.Assays with antibodies directed against the N-terminal parts of CgA and CgB showed sufficient interspecies cross-reactivity to allow comparative quantification of the circulating levels in man, cattle, sheep, goat, pig and horse. Assays measuring the intact human or bovine CgA were not suitable for comparative purposes in samples from sheep, goat, pig and horse. Molecular interactions between vasostatin immunoreactive material and intact bovine CgA were demonstrated in gel permeation studies, suggesting that conclusions about the degree of N-terminal processing from elution profiles should be made with caution.Reliable interspecies comparison of chromogranins is difficult, but measurements with region-specific assays may be helpful to study concentrations of chromogranins and chromogranin-related peptides.

show abstract

A polyclonal antiserum against chromogranin A and B - a new sensitive marker for neuroendocrine tumours

Cited by 79 publications

References 21 publications

A New Human Chromogranin “A” Immunoradiometric Assay for the Diagnosis of Neuroendocrine Tumours

A New Human Chromogranin “A” Immunoradiometric Assay for the Diagnosis of Neuroendocrine Tumours

A new human chromogranin A (CgA) immunoradiometric assay involving monoclonal antibodies raised against the unprocessed central domain (145-245)

Characterisation of N-terminal chromogranin A and chromogranin B in mammals by region-specific radioimmunoassays and chromatographic separation methods

Contact Info

Product

Resources

About